SEC filings and other documents

Strategic divestiture funds clinical pipeline and special dividend, positioning for growth.

$100M Apotex deal and FDA approvals mark a strategic pivot to pipeline innovation.

Double-digit revenue growth and global expansion in 2025, with strong pipeline progress.

Q3 revenue grew 12% year-over-year, driven by new products and international expansion.

Q2 2025 revenue up 10% to $10.8M; clinical and international expansion drive growth.

Q1 revenue up 38% to $11.7M, driven by Vibativ milestone and clinical pipeline progress.

Q4 revenue up 11.6%, pipeline and brands advanced, double-digit growth expected in 2025.

Q3 net revenue reached $9.1M, with gross margin up to 85% and new product advances.

Q2 revenue up 16% sequentially, driven by Kristalose, Vibativ, and Sancuso growth.